Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a phase I, multicenter, open-label dose escalation and expansion study to evaluate
genakumab alone and in combination with tislelizumab in adult patients with advanced solid
malignancies.